eli lilly q4 - Search News

Eli Lilly’s stock falls

Eli Lilly stock down on Q4 guidance miss

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Reuters · 21h

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

Newsable Asianet News on MSN · 19h

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the stock’s worst day since March 15, 2021. The decline followed a disappointing fourth-quarter revenue outlook update,

18h

Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 with $61B Revenue Potential

Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...

19h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Pharmaceutical Technology1h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Hosted on MSN2d

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

21h

Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

20hon MSN

Hims & Hers in focus as Eli Lilly obesity drug sales disappoint

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

pharmaphorum10m

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

13h

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

bovnews19h

Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

19h

Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast

Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results